In a recent webinar from Pharmaphorum, YuzuYello’s Director of Learning Strategy Imre Varju joined Caudex’s Medical Strategy Director Lynda Chang and Senior Medical Strategy Director Jane Blyth along with Bayer Pharmaceuticals’ Dr. Kristian Johnson to discuss how cell and gene therapy (CGT) is revolutionizing the treatment of rare diseases.
Panelists explained how CGTs “aim to correct or modify the underlying causes of disease,” and explored complexities such as clinical trial design, patient recruitment and long-term safety and affordability.
